Overview of Dr. Francis
Dr. Jasmine Francis is an ophthalmologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from New York University Grossman School of Medicine and has been in practice 10 years. She is one of 23 doctors at Memorial Sloan Kettering Cancer Center who specialize in Ophthalmology. She has more than 100 publications and over 500 citings.
Office
160 East 53rd Street
New York, NY 10022
Education & Training
- Icahn School of Medicine at Mount Sinai/New York Eye and Ear Infirmary at Mount SinaiResidency, Ophthalmology, 2008 - 2011
- New York University School of MedicineClass of 2007
Certifications & Licensure
- NY State Medical License 2008 - 2026
- American Board of Ophthalmology Ophthalmology
Publications & Presentations
PubMed
- 26 citationsImmune Checkpoint Inhibitor-Associated Optic Neuritis.Jasmine H. Francis, Korey Jaben, Bianca Santomasso, Julia Canestraro, David H. Abramson
Ophthalmology. 2020-05-08 - 282 citationsAltered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice.Alena Lira, Mingming Zhou, Nathalie Castanon, Mark S. Ansorge, Joshua A. Gordon
Biological Psychiatry. 2003-11-15 - 7 citationsRefractive Shifts and Changes in Corneal Curvature Associated With Antibody-Drug ConjugatesJulia Canestraro, Malin Hultcrantz, Shanu Modi, Paul A. Hamlin, Alexander N. Shoushtari
Cornea. 2021-11-24
Journal Articles
- Growth Patterns of Survivors of Retinoblastoma Treated with Ophthalmic Artery ChemosurgeryJasmine H Francis, Y Pierre Gobin, David H Abramson, PLoS One
- Total Retinal Detachments Due to Retinoblastoma: Outcomes Following Intra-Arterial chemotherapy/ophthalmic Artery ChemosurgeryIra J Dunkel, Jasmine H Francis, Y Pierre Gobin, Scott E Brodie, David H Abramson, PLoS One
- Clinical and Morphologic Characteristics of MEK Inhibitor–Associated RetinopathyJasmine Francis, MD, Ophthalmology
Press Mentions
- Hearing Evaluations in Children with Retinoblastoma Treated with Intra-Arterial Carboplatin Chemotherapy: A Single Institution ReviewSeptember 10th, 2024
- FDA Approves First Treatment for Patients with All Forms of HistiocytosisJanuary 30th, 2023
- Doctors Identify an Eye Cancer CulpritSeptember 13th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: